Genentech, Inc.
NEWS
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.
In a Phase III trial, a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.
This approval marks the first new initial treatment option for this difficult-to-treat type of lung cancer in more than 20 years.
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
Tecentriq is a monoclonal antibody that binds with the PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells. It blocks interactions with both PD-1 and B7.1 receptors.
The study showed that artificial intelligence can be used to provide widespread, cost-effective eye screenings via telemedicine to assist ophthalmologists in improving vision outcomes.
January was a rough month for many pharma employees in California, as several companies pulled the trigger on layoffs, or announced coming layoffs that will affect hundreds of employees.
There is a concept held dear by many that there is strength in diversity. At South San Francisco-based Genentech, that is a concept also embraced by Sara Kenkare-Mitra, senior vice president of development sciences.
JOBS
IN THE PRESS